Related references
Note: Only part of the references are listed.Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2020)
Analysis of the genetic variants associated with circulating levels of sgp130. Results from the IMPROVE study
Alice Bonomi et al.
GENES AND IMMUNITY (2020)
Global Transcriptional Profiling Reveals Novel Autocrine Functions of Interleukin 6 in Human Vascular Endothelial Cells
Liza U. Ljungberg et al.
MEDIATORS OF INFLAMMATION (2020)
IL-6 trans-Signaling Impairs Sprouting Angiogenesis by Inhibiting Migration, Proliferation and Tube Formation of Human Endothelial Cells
Mulugeta M. Zegeye et al.
CELLS (2020)
Interleukin 6 trans-signalling and risk of future cardiovascular events
Louise Ziegler et al.
CARDIOVASCULAR RESEARCH (2019)
A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity
Mickael Rosa et al.
NPJ GENOMIC MEDICINE (2019)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Reassessing the Mechanisms of Acute Coronary Syndromes The Vulnerable Plaque and Superficial Erosion
Peter Libby et al.
CIRCULATION RESEARCH (2019)
Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction
Hilde E. Groot et al.
CLINICAL RESEARCH IN CARDIOLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide
Roxana Loperena et al.
CARDIOVASCULAR RESEARCH (2018)
Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells
Mulugeta M. Zegeye et al.
CELL COMMUNICATION AND SIGNALING (2018)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers
Ravi Dhingra et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2017)
Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein: protein interaction and modulates its downstream signaling
Ralph Adams et al.
SCIENTIFIC REPORTS (2017)
IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals
Kathryna Fontana Rodrigues et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2017)
Association of tobacco use and cessation with coronary atherosclerosis
Michael K. Cheezum et al.
ATHEROSCLEROSIS (2017)
Mediation Analysis: A Practitioner's Guide
Tyler J. VanderWeele
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 37 (2016)
Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction
Ilais Moreno Velasquez et al.
ATHEROSCLEROSIS (2015)
Inflammation and plaque vulnerability
G. K. Hansson et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Statistical mediation analysis with a multicategorical independent variable
Andrew F. Hayes et al.
BRITISH JOURNAL OF MATHEMATICAL & STATISTICAL PSYCHOLOGY (2014)
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Xin Yao et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Targeting Interleukin-6 in Rheumatoid Arthritis
Md Yuzaiful Md Yusof et al.
DRUGS (2013)
Endothelial dysfunction and hypertension in aging
Yukihito Higashi et al.
HYPERTENSION RESEARCH (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
Toshio Tanaka et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Association of interleukin-6 circulating levels with coronary artery disease: A meta-analysis implementing mendelian randomization approach
Wenquan Niu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
The interleukin-6 pathway and atherosclerosis
S. Matthijs Boekholdt et al.
LANCET (2012)
The interleukin 6 pathway and atherosclerosis
Juergen Scheller et al.
LANCET (2012)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
Nadeem Sarwar et al.
LANCET (2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
Stephen Kaptoge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Haemostatic and inflammatory markers are independently associated with myocardial infarction in men and women
Patrik Wennberg et al.
THROMBOSIS RESEARCH (2012)
Inflammation and Hypertension: The Interplay of Interleukin-6, Dietary Sodium, and the Renin-Angiotensin System in Humans
Bindu Chamarthi et al.
AMERICAN JOURNAL OF HYPERTENSION (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction
Silvia S. Barbieri et al.
CARDIOVASCULAR RESEARCH (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Ligand binding assays at equilibrium: validation and interpretation
Edward C. Hulme et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and Improves Systemic Insulin Action
F. Thomas Wunderlich et al.
CELL METABOLISM (2010)
The Vasterbotten Intervention Programme: background, design and implications
Margareta Norberg et al.
GLOBAL HEALTH ACTION (2010)
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Olle Melander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
How much is too much? Interleukin-6 and its signalling in atherosclerosis
Harald Schuett et al.
THROMBOSIS AND HAEMOSTASIS (2009)
Relation of smoking status to a panel of inflammatory markers: The Framingham offspring
Yamini S. Levitzky et al.
ATHEROSCLEROSIS (2008)
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women - The Reynolds Risk Score
Paul M. Ridker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Multiple biomarkers for the prediction of first major cardiovascular events and death
Thomas J. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Interleukin 6: from bench to bedside
Norihiro Nishimoto et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Pathophysiology of coronary artery disease
P Libby et al.
CIRCULATION (2005)
Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects
G Vázquez-Oliva et al.
JOURNAL OF HUMAN HYPERTENSION (2005)
The pathophysiology of cigarette C-V smoking and cardiovascular disease - An update
JA Ambrose et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans
R Starkie et al.
FASEB JOURNAL (2003)
The events registration and survey procedures in the Northern Sweden MONICA Project
B Stegmayr et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2003)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Raised interleukin-6 levels in obese patients
L Roytblat et al.
OBESITY RESEARCH (2000)
Share Paper
